Once-monthly ibandronic acid cost effective
- PDF / 124,812 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 94 Downloads / 160 Views
rnshaw SR, et al. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK prospective RECT. Journal of Bone and Mineral Research 21 (Suppl. 1): 416-417, Sep 2006. 2. Grima DT, et al. Cost-effectiveness of risedronate versus ibandronate: impact of persistence. Journal of Bone and Mineral Research 21 (Suppl. 1): 181, Sep 2006. 801052006
* PERsistence Study of Ibandronate verSus alendronaTe ** All costs were reported in 2004 values; direct health resource costs for fracture states were discounted at a 3.5% annual rate.
1173-5503/10/0516-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 18 Nov 2006 No. 516
Data Loading...
